Carcinogenicity of radiation doses caused by the Chernobyl fall-out in Sweden, and prevention of possible tumors

Springer Science and Business Media LLC - Tập 4 - Trang 1-5 - 1987
Peter Reizenstein1,2
1Division of Hematology, Karolinska Hospital and Institute, Stockholm, Sweden
2Division of Medicine, National Institute of Radiation Protection, Stockholm, Sweden

Tóm tắt

The fallout from the Chernobyl reactor resulted in radioactive fall-out in eeastern Sweden leading to a ground radiation intensity of between 2 and 500 μR h−1 above the 10–15 μR h−1 background, an average external cumulative dose of about 3–4 mSv (0.3–0.4 rem) to about 1 million people, or about 3500 man-Sv (350,000 man-rem) over 50 years, or 70 man-Sv per year with a maximum dose to a few individuals of 40 mSv. The corresponding figures reported for civilians around Chernobyl is 8.6 million man-rem in 1986 and 29 million man-rem over 50 years, or 600,000 man-rem (equivalent to about 6000 man-Sv) per year. If Swedish doses are averaged over the whole population, the average is about 1 mSv or 10,000 man-Sv, or 200 man-Sv per year. The thyroid uptake of131I is approximately 0.1–0.2 kBq (0.005 μCi) and the total body uptake of137Cs, 1 kBq (0.03 μCi), resulting in an approximate internal dose of 0.02 mSv. If a linear dose-response curve is assumed,an increase of the normal cancer mortality incidence in the million Swedes affected by 3500 man-Sv per 50 years from 200,000 to about 200,070 can be assumed. Corresponding figures for all of Sweden are 8,000,000 inhabitants, 7000 man-Sv, 1,720,000 normal cancer deaths, and 1,720,140 expected cancer deaths. Corresponding figures reported for the population outside the 30 km evacuation zone around Chernobyl are 300,000 man-Sv, and an increase from 6,800,000 cancer deaths per 50 years to 6,806,000 cancer deaths.

Tài liệu tham khảo

Upton A C: Biological aspects of radiation carcinogenesis, inBoice J D, Fraumeni J D (eds).Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 9. New York, Raven Press (1983). Goodhead D T: Deductions from cellular studies of inactivation, mutagenesis, and transformation, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 369. New York, Raven Press (1984). Gould M N: Radiation initiation of carcinogenesisin vivo: a rare or common cellular event, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 347. New York, Raven Press (1984). Beebe G W: Developments in assessing carcinogenic risks from radiation, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological significance, p. 457. New York, Raven Press (1984). Rothman K J: Significance of studies of low-dose radiation fallout in the Western United States, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 73. New York, Raven Press (1984). Monson R R, MacMahon B: Prenatal X-ray exposure and cancer in children, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 97. New York, Raven Press (1984). MacMahon B, Hutchinson G B: Prenatal X-ray and childhood cancer.Acta Unio Int Contra Cancrum 20, 1172 (1964). Finch S C: Leukemia and lymphoma in atomic bomb survivors, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 37. New York, Raven Press (1983). Howe G R: Epidemiology of radiogenic breast cancer, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 119. New York, Raven Press (1983). National Academy of Sciences:The Effects in Populations of Exposure to Low Levels of Radiation. Washington National Academy of Sciences Press (1980). Katz H, Schull W: Studies of the mortality of A-bomb survivors—7. Mortality 1950–1978: Part 1. Cancer mortality.Radiat Res 90, 395 (1982). Stewart A, Webb J, Hewitt M A: A survey of childhood malignancies.Br Med J 1, 1495 (1958). British Radiological Protection Association: The irradiation of volunteers in medical research.Br Med J 1, 7 (1976). Use of ionizing radiation and radionuclides on human beings for medical research. Training and non-medical purposes. Tech. Rept. Series 611, Geneva, World Health Organisation (1977). Shore R E, Woodward E D, Hempelmann L H: Radiation-induced thyroid cancer, in Boice J D, Fraumeni J F (eds):Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 131. New York, Raven Press (1984). Modan B: Radiation-induced head and neck tumors.Lancet i, 277 (1974). Schull W J: Atomic bomb survivors: patterns of cancer risks, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 21. New York, Raven Press (1983). Gibson R: Irradiation in the epidemiology of leukemia among adults.J Natl Cancer Inst 48, 301 (1972). Green M H: Interaction between radiotherapy and chemotherapy in human leukomogenesis, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 129. New York, Raven Press (1984). Linos A, Gray J E, Orvis A L, Kyle R A O’Fallon W M, Kurland L T: Low-dose radiation and leukemia.New Engl J Med 302, 1101 1980. Lyon L J, Gardner J W, West D W, Schussman L: Further information on the association of childhood leukemias with atomic fallout, in Enström J E: The nonassociation of fallout radiation with childhood leukemia in Utah, inBanbury Report: 4. Cancer Incidence in Defined Populations, pp. 147–186. Cold Spring Harbour (1980). Matanoski G M, Sartwell P, Elliot E, Tonascia J, Sternberg A: in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 83. New York, Raven Press (1983). van Kaick G, Muth H, Kaul A, Immich H, Liebermann D, Lorenz D, Lorenz W J, Lührs H, Scheer K E, Wagner G, Wegener K, Wesch H: Results of the German thorotrast study, in Boice J D Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 253. New York, Raven Press (1984). Russel J G B: How much can the NHS afford to spend to save a life or avoid a severe disability?Lancet i, 281 (1985). Holm L E: Thyroid cancer after exposure to radioiodine, inDie Hypothesen im Strahlenschutz, pp. 35–56. Stuttgart, Thieme (1985). Holm L E, Dahlqvist I, Engs N, Israelsson A, Lungdell G: Malignant thyroid tumors after iodine-131 therapy.New Engl J Med 303, 188 (1980). Holm L E, Lundell G, Walinder G: Incidence of malignant thyroid tumors in humans after exposure to diagnostic doses of iodine-131. I. Retrospective cohort study.J Natl Cancer Inst 64, 1056 (1980). Holm L E, Eklund G, Lundell G: Incidence of malignant thyroid tumors in humans after exposure to diagnostic doses of iodine-131. II. Estimation of thyroid gland size, thyroid radiation dose, and predicted versus observed number of malignant thyroid tumors.J Natl Cancer Inst 65, 1221 (1980). Holm L E: Malignant disease following iodine-131 therapy in Sweden, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 263. New York, Raven Press (1984). Holm L E: Carcinogenic and genetic risks of ionizing radiation with special reference to radioiodines, in Beckers C. (ed):Thyroid Diseases, p. 159 (1982). Pochin J E: Leukaemia following radioiodine treatment of thyrotoxicosis.Br Med J 2, 1545 (1960). Boice J D, Day N E, Andersen Aet al.: Cancer risk following radiotherapy of cervical cancer, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 161. New York, Raven Press (1984). Wagoner J K: Leukemia and other malignancies following radiation therapy for gynecological disorders, in Boice J D, Fraumeni J F (eds):Progress in Cancer Research and Therapy, Vol. 26,Radiation Carcinogenesis: Epidemiology and Biological Significance, p. 153 New York, Raven Press (1984). Thakur M L, McAfee J G: The significance of chromosomal abberations in indium-111-labeled lymphocytes.J Nucl Med 25, 922 (1984). Najean Y, Dresch C: in Mathé G, Reizenstein P (eds):Clinical Trials in Oncology: Methods, Errors, Ethics, and Results, Geneva Bioscience Ediprint (1986). Tubiana M: Paper given at EORTC Plenary Meeting, Paris (1983). Tamplin A [in Swedish]:Dagens Nyheter (Swedish Daily) (1986). Ringdén O, Båryd I, Johansson B, Bolme P, Gahrton G, Groth C G, Klintmalm G, Lundgen G, Lönnqvist B: Increased mortality in bone marrow transplant recipients accidentally receiving an increased dose rate of total body irradiation.Ann Mtg Eur Bone Marrow Transpl Group 9 (1983) (suppl. toExp Hemat). Reizenstein P: Stencilled information to Swedish medical personnel, 5 and 21 May (1986). Reizenstein P, Larsson S, Ekman M, Stenke L: in preparation. Lindell B, Beninson D: Chernobyl reactor accident. Provisional report of a WHO consultation 6 May 1986 (stencilled) KP/CEH 129. Horisberger N, Hasselgren A, Jolly D, Reizenstein Pet al.: Summary report of a WHO working group on the impact of medical decision-making on hospital cost. (stencilled) ICP/PHC 601/m01(S) 15 April (1986). Larsson L G, Bengtsson G, Walinder G: Radiation and health risks (in Swedish). IVA Beijer symp. 28 August 1986 (stencil). Date on operational and emergency staff of the nuclear power plant who were exposed to radiation: size of the doses received and consequences for health. Annex 7 to draft of IAEA Safety Series Publication:Medical Handling of Accidentally Exposed Individuals, IAEA Technical Committee, Paris 27 October 1986 (stencil). Greene M H, Harris E L, Gerhenson D Met al.: Melphalan may be a more potent leukemogen than cyclophosphamide.Ann Intern Med 105, 360 (1986).